Voloridge Investment Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Voloridge Investment Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-564,044	Closed	-$23.8M	–	1403
2024 Q1	$23.8M	Sell	564,044 -335,980	-37%	-$14.1M	0.09%	288
2023 Q4	$38.2M	Buy	+900,024	New	+$25.9M	0.15%	181
2022 Q1	–	Sell	-48,289	Closed	-$1.57M	–	1773
2021 Q4	$1.57M	Sell	48,289 -43,918	-48%	-$1.55M	0.01%	1143
2021 Q3	$2.72M	Buy	+92,207	New	+$2.59M	0.02%	933

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Voloridge Investment Management's CERE Position: Q2 2024 in Review

Voloridge Investment Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 564,044 shares — an estimated $23.8M sold.

Voloridge Investment Management first reported a position in CERE in Q3 2021 and held it in 4 quarters. The position peaked at $38.2M in Q4 2023. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

Voloridge Investment Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Voloridge Investment Management sold 564,044 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $23.8M.
Voloridge Investment Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
Voloridge Investment Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $38.2M in Q4 2023.
231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Voloridge Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.